Login / Signup

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Rino RappuoliMariagrazia PizzaVega MasignaniKumaran Vadivelu
Published in: Expert review of vaccines (2018)
Invasive meningococcal disease is uncommon and sufficiently powered efficacy studies were not feasible during 4CMenB development. Additionally, several thousand genetically diverse invasive MenB strains circulate globally, varying widely in surface protein expression. This posed significant challenges in predicting clinical protection with MenB vaccines. Five years of 4CMenB use post-licensure confirm the clinical benefit of vaccination as predicted during development. Preliminary evidence suggests an extended impact on other meningococcal serogroups and Neisseria gonorrhoeae.
Keyphrases
  • escherichia coli